Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.

Breathing is essential for life, yet for many individuals suffering from chronic respiratory issues such as asthma and COPD, it can feel like a constant struggle. The good news is that ...

Conventional treatments for allergic rhinitis may also improve asthma outcomes in patients with both conditions. Read now!

The parents of a 22-year-old Wisconsin man who died after an asthma attack have filed a lawsuit against Walgreens and ...

The parents of a young Wisconsin man have sued Walgreens and pharmacy benefit manager OptumRx over their son’s death from an ...

Blood tests for cyclic adenosine monophosphate may be a simple and useful option for diagnosing asthma and determining its ...

In a world where respiratory issues are increasingly common, finding practical solutions can be daunting. Breathe Drops ...

The family of a Wisconsin man is suing after they say he died from an asthma attack when his medication price rose from $66 ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

Blue Cross Blue Shield company Health Care Service Corporation is limiting access for in-office administration of asthma ...

A small proportion of veterans who went from a metered-dose inhaler to a dry-powder inhaler had to revert to the metered-dose ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- A set of chameleon-like immune cells could be contributing to severe asthma in ...